公开(公告)号：US20200300870A1

公开(公告)日：2020-09-24

申请号：US16753295

申请日：2018-10-02

Applicant: Neuracle Science Co., Ltd. ,  Korea University Research and Business Foundation

Inventor： Jae Young SEONG ,  Byung Joo HAM ,  Min-Hyeok LEE ,  Nui HA

IPC: G01N33/68 ,  C12Q1/6883

Abstract: The present disclosure relates to a method of diagnosing a mood disorder in a subject comprising measuring serum FAM19A5 concentration with an antagonist (e.g., an antibody or antigen-binding fragment thereof) that specifically binds to FAM19A5. The present disclosure also relates to a method of treating a mood disorder in a subject in need thereof comprising administering to the subject an FAM19A5 antagonist.

公开(公告)号：US20200270337A1

公开(公告)日：2020-08-27

申请号：US16807902

申请日：2020-03-03

Applicant: Neuracle Science Co., Ltd.

Inventor： Jae Young SEONG ,  Jong Ik HWANG ,  Woong SUN ,  Eun Bee CHO ,  Won-Ki KIM

IPC: C07K16/24 ,  C07K14/47 ,  C12Q1/6886 ,  A61K38/17 ,  A61K48/00 ,  C07K16/18 ,  C12N15/113 ,  G01N33/577 ,  G01N33/68

Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.

公开(公告)号：US20170121401A1

公开(公告)日：2017-05-04

申请号：US15404011

申请日：2017-01-11

Applicant: Neuracle Science Co., Ltd.

Inventor： Jae Young SEONG ,  Jong Ik Hwang ,  Woong Sun ,  Eun Bee Cho ,  Won-Ki Kim

IPC: C07K16/24 ,  G01N33/577 ,  G01N33/68

CPC classification number: C07K16/24 ,  A61K38/1709 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/4701 ,  C07K14/4702 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/141 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/577 ,  G01N33/6896 ,  G01N2333/47

Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.